from seed
to summit.

We fuel the ascent of biotech pioneers.

Investing in computationally-enabled seed stage platforms scaling the highest peaks of innovation.

Teams We're Backing

Fauna Bio is harnessing 100 million years of evolution to cure human disease. Using its proprietary Convergence™ AI platform, the company analyzes genomic data from animals that have naturally evolved to resist specific illnesses. By identifying and replicating these disease-resistant mechanisms, Fauna Bio discovers novel drugs for humans, with its lead asset targeting heart disease associated with Pulmonary Hypertension.

Read more here.

Modulate Bio's AI-powered discovery platform is engineered to overcome the limitations of current neurological treatments. By precisely designing novel GABAA positive allosteric modulators, the company is developing a pipeline of differentiated therapies for Essential Tremor, epilepsy, and anxiety that promise greater efficacy without the common side effects of today's standards of care.

Read more here.

Screenshot 2026-03-02 at 10.50.32 AM.png

Coding Bio's AI-powered discovery platform is engineered to overcome the limitations of current immunotherapies. By optimizing for functionality instead of binding affinity, the company is developing a pipeline of differentiated cancer therapies—such as treatments for multiple myeloma—that promise better dosing capabilities and greater efficacy without minimized systemic toxicity of today's standards of care.